Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin

Vaccine
Larry R SmithRonald B Moss

Abstract

Development of vaccines against highly pathogenic avian influenza virus H5N1 subtypes posing a pandemic threat remains a priority. Limitations in manufacturing capacity and production time of conventional inactivated vaccines highlight the need for additional approaches. We conducted two double-blind, placebo-controlled phase 1 studies involving a total of 103 healthy adults who received two intramuscular injections of Vaxfectin-adjuvanted plasmid DNA vaccine or placebo 21 days apart. Vaccine cohorts received either a monovalent vaccine containing an A/Vietnam/1203/04 H5 hemagglutinin-encoding plasmid or a trivalent vaccine with plasmids encoding H5, NP, and M2 proteins in doses from 0.1 to 1mg of DNA/injection. All doses were well tolerated without vaccine-related serious adverse events or discontinuations. In the monovalent cohorts, hemagglutination inhibition (HI) titers of > or =40 and 4-fold rises from baseline were achieved in 47-67% of subjects and H5-specific T-cell responses in 75-100%. Trivalent cohorts had lower HI response rates (< or = 20%), but 72% of subjects achieved T-cell and/or antibody responses to one or more antigens. Vaxfectin-adjuvanted monovalent H5 DNA vaccines were well tolerated and induced HI respon...Continue Reading

References

Jul 27, 2002·Emerging Infectious Diseases·Suzanne L EpsteinJacqueline M Katz
Apr 11, 2003·Vaccine·Catherine Gerdil
Mar 31, 2006·The New England Journal of Medicine·John J TreanorMark Wolff
Jul 24, 2007·Current Opinion in Pharmacology·Wendy A Keitel, Robert L Atmar
Jan 18, 2008·The New England Journal of Medicine·UNKNOWN Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian InfTimothy M Uyeki
Feb 12, 2008·The Journal of Infectious Diseases·David I BernsteinHeather Hill
May 1, 2008·The Journal of Infectious Diseases·Mary K WlochMichael Boeckh
Jun 14, 2008·The New England Journal of Medicine·Hartmut J EhrlichUNKNOWN Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team
May 9, 2009·The New England Journal of Medicine·Robert B Belshe

❮ Previous
Next ❯

Citations

Dec 21, 2013·Archives of Virology·Qin ChenGuimei He
Oct 19, 2011·Journal of Biomedicine & Biotechnology·Marine L B HillaireGuus F Rimmelzwaan
Jul 17, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Luis A BritoAndrew J Geall
Jul 19, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bernadette FerraroDavid B Weiner
Jul 5, 2013·Clinical Microbiology Reviews·Sook-San Wong, Richard J Webby
Nov 23, 2010·Expert Review of Vaccines·Suzanne L Epstein, Graeme E Price
Sep 8, 2015·Vaccines·Lidewij C M WiersmaRory D de Vries
Sep 26, 2012·Expert Review of Vaccines·Sang-Moo KangRichard W Compans
Feb 9, 2012·Expert Review of Vaccines·Fadi Saade, Nikolai Petrovsky
Sep 8, 2015·Vaccines·Lei DengXavier Saelens
Jul 26, 2012·Expert Review of Vaccines·Karen Smith KorsholmDennis Christensen
Sep 15, 2015·Expert Opinion on Drug Delivery·Małgorzata Anna MarćCarlos Gamazo
Dec 2, 2010·Expert Opinion on Drug Delivery·Sean M SullivanAlain Rolland
Dec 8, 2010·Expert Opinion on Biological Therapy·Gian Vincenzo Zuccotti, Valentina Fabiano
Mar 4, 2011·Expert Opinion on Biological Therapy·Nicola PrincipiPaola Marchisio
Jun 4, 2013·Virus Research·Mariana BazKanta Subbarao
Jul 23, 2011·Vaccine·Janine R DankoKevin R Porter
Jul 6, 2010·Vaccine·Julia A MisplonSuzanne L Epstein
Dec 18, 2015·Future Microbiology·Han Zhang, Mohamed E El Zowalaty
Sep 25, 2012·Influenza and Other Respiratory Viruses·Sarah C Gilbert
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Cécile van ElsFredrik Oftung
Jun 7, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Peter C SoemaGideon F A Kersten
Mar 19, 2014·Colloids and Surfaces. B, Biointerfaces·Su-Eon Jin, Chong-Kook Kim
Nov 13, 2012·PLoS Pathogens·Christine Rueckert, Carlos A Guzmán

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.